Daehan New Pharm Co. Ltd Total Liabilities
Daehan New Pharm Co. Ltd total liabilities. Based on the latest financial reports, Daehan New Pharm Co. Ltd (054670) has total liabilities worth ₩122.10 Billion KRW (≈ $82.74 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Daehan New Pharm Co. Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Daehan New Pharm Co. Ltd (2014–2024)
Total liabilities of Daehan New Pharm Co. Ltd from 2014 to 2024. This chart illustrates how Daehan New Pharm Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 054670 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Daehan New Pharm Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Daehan New Pharm Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Digihost Technology Inc
V:DGHI
|
Canada | CA$12.34 Million |
|
Viewbix Inc. Common Stock
NASDAQ:VBIX
|
USA | $5.77 Million |
|
Vertical Aerospace Ltd
NYSE:EVTL
|
USA | $128.35 Million |
|
Elton International Trading Company S.A
AT:ELTON
|
Greece | €51.37 Million |
|
Strongpoint ASA
OL:STRO
|
Norway | Nkr529.41 Million |
|
Maison Internationale de lInformatique M2I SAS
PA:ALMII
|
France | €24.90 Million |
|
RS Automation Co.Ltd
KQ:140670
|
Korea | ₩33.34 Billion |
|
Vizsla Copper Corp
V:VCU
|
Canada | CA$2.09 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Daehan New Pharm Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Daehan New Pharm Co. Ltd.
Liquidity & Leverage Metrics
Daehan New Pharm Co. Ltd Total Liabilities Ratios Explained
Daehan New Pharm Co. Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Daehan New Pharm Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Daehan New Pharm Co. Ltd (2014–2024)
The table below shows the annual total liabilities of Daehan New Pharm Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩95.85 Billion ≈ $64.95 Million |
+41.84% |
| 2023-12-31 | ₩67.57 Billion ≈ $45.79 Million |
+1.76% |
| 2022-12-31 | ₩66.40 Billion ≈ $45.00 Million |
-11.68% |
| 2021-12-31 | ₩75.18 Billion ≈ $50.95 Million |
-1.01% |
| 2020-12-31 | ₩75.95 Billion ≈ $51.47 Million |
+13.62% |
| 2019-12-31 | ₩66.84 Billion ≈ $45.30 Million |
+1.80% |
| 2018-12-31 | ₩65.66 Billion ≈ $44.49 Million |
-6.33% |
| 2017-12-31 | ₩70.09 Billion ≈ $47.50 Million |
+17.77% |
| 2016-12-31 | ₩59.52 Billion ≈ $40.33 Million |
+7.38% |
| 2015-12-31 | ₩55.43 Billion ≈ $37.56 Million |
-2.03% |
| 2014-12-31 | ₩56.58 Billion ≈ $38.34 Million |
-- |
About Daehan New Pharm Co. Ltd
Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormo… Read more